| ATAIBECKLEY INC. O.N. |
| USA |
| Gesundheit |
| US04650F1012 / A41WEP |
| B72 (Frankfurt) / ATAI (NASDAQ) |
| FRA:B72, ETR:B72, B72:GR, NASDAQ:ATAI |
| - |
| https://www.ataibeckley.c.. |
|
AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for mental health disorders. The company concentrates on psychedelic-based and other novel neuroactive compounds designed to offer rapid-acting, du..
>Volltext.. |
| 2344.23 Mio. EUR |
| 2148.44 Mio. EUR |
| 3.83 Mio. EUR |
| -124.62 Mio. EUR |
| -572.31 Mio. EUR |
| -1.87 EUR |
| 1.61 Mio. EUR |
| 144.58 Mio. EUR |
| -110.43 Mio. EUR |
| 7.91 |
| 1009.83% |
| -979.14% |
| - |
| - |
| - |
| - |
| ATAIBECKLEY, ATAI BECKLEY |
| 26.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|